Dyslipidemia is associated with a poor prognosis of breast cancer in patients receiving neoadjuvant chemotherapy

被引:8
|
作者
Ma, Youzhao [1 ,2 ]
Lv, Minhao [1 ,2 ]
Yuan, Peng [1 ,2 ]
Chen, Xiuchun [1 ,2 ]
Liu, Zhenzhen [1 ,2 ]
机构
[1] Zhengzhou Univ, Affiliated Canc Hosp, Henan Breast Canc Ctr, Dept Breast Dis, 127 Dongming Rd, Zhengzhou 450008, Peoples R China
[2] Henan Canc Hosp, 127 Dongming Rd, Zhengzhou 450008, Peoples R China
关键词
Breast cancer; Dyslipidemia; Pathological complete response; Neoadjuvant therapy; Disease-free survival; LIPID-METABOLISM; RECURRENCE; EXEMESTANE; MORTALITY;
D O I
10.1186/s12885-023-10683-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundLipid metabolism disorders may be involved in the occurrence and development of breast cancer. This study aimed to investigate the serum lipid changes during neoadjuvant chemotherapy for breast cancer and the effect of dyslipidemia on the prognosis of breast cancer patients.MethodsWe collected the data from 312 breast cancer patients who underwent surgery after receiving standard neoadjuvant therapy. chi(2) test and T-test were employed to analyze the effect of chemotherapy on the serum lipid metabolism of patients. The effects of dyslipidemia on the disease-free survival (DFS) of patients with breast cancer were analyzed by chi(2) test and COX regression analysis.ResultsA total of 56 out of 312 patients (17.9%) suffered from relapse. The baseline serum lipid level of the patients was significantly correlated with their age and body mass index (BMI) (p < 0.05). Chemotherapy increased the levels of triglycerides, total cholesterol, and low-density lipoprotein cholesterol, but decreased the level of high-density lipoprotein cholesterol (p < 0.001). Preoperative dyslipidemia was significantly associated with the axillary pCR rate (p < 0.05). COX regression analysis revealed that the full-course serum lipid level (HR = 1.896 [95%CI 1.069-3.360]; p = 0.029), N stage (HR = 4.416 [95%CI 2.348-8.308]; p < 0.001) and the total pCR rate (HR = 4.319 [95%CI 1.029-18.135]; p = 0.046) acted as prognostic factors affecting DFS in breast cancer. The relapse rate in patients with a high level of total cholesterol was higher than that in patients with a high level of triglycerides (61.9% vs 30.0%; p < 0.05).ConclusionsDyslipidemia deteriorated after chemotherapy. The full-course serum lipid level may thus serve as a blood marker for predicting breast cancer prognosis. Serum lipids should therefore be closely monitored in breast cancer patients throughout the treatment course, and patients with dyslipidemia should be treated in a timely manner.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Dyslipidemia is associated with a poor prognosis of breast cancer in patients receiving neoadjuvant chemotherapy
    Youzhao Ma
    Minhao Lv
    Peng Yuan
    Xiuchun Chen
    Zhenzhen Liu
    [J]. BMC Cancer, 23
  • [2] Pretreatment Depressive Status Associated with Poor Nutrition and Prognosis in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
    Xiao, Xiaodan
    Huang, Siyin
    Gan, Chengju
    Quan, Xiaoli
    Xiang, Yali
    Zheng, Baojia
    [J]. NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2023, 75 (04): : 1223 - 1232
  • [3] Lymphocyte-to-Monocyte Ratio is Associated with the Poor Prognosis of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
    Ma, Youzhao
    Zhang, Jingyang
    Chen, Xiuchun
    [J]. CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 1571 - 1580
  • [4] Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment
    Peter A Fasching
    Katharina Heusinger
    Lothar Haeberle
    Melitta Niklos
    Alexander Hein
    Christian M Bayer
    Claudia Rauh
    Ruediger Schulz-Wendtland
    Mayada R Bani
    Michael Schrauder
    Laura Kahmann
    Michael P Lux
    Johanna D Strehl
    Arndt Hartmann
    Arno Dimmler
    Matthias W Beckmann
    David L Wachter
    [J]. BMC Cancer, 11
  • [5] Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment
    Fasching, Peter A.
    Heusinger, Katharina
    Haeberle, Lothar
    Niklos, Melitta
    Hein, Alexander
    Bayer, Christian M.
    Rauh, Claudia
    Schulz-Wendtland, Ruediger
    Bani, Mayada R.
    Schrauder, Michael
    Kahmann, Laura
    Lux, Michael P.
    Strehl, Johanna D.
    Hartmann, Arndt
    Dimmler, Arno
    Beckmann, Matthias W.
    Wachter, David L.
    [J]. BMC CANCER, 2011, 11
  • [6] Does immunohistochemical marker conversion affect the prognosis in breast cancer patients receiving neoadjuvant chemotherapy?
    Uzun, Mehmet
    Atag, Elif
    Yildirim, Eda Caliskan
    Keser, Murat
    Semiz, Huseyin Salih
    Unal, Olcun Umit
    [J]. SCIENTIFIC REPORTS, 2024, 14 (01):
  • [7] Skeletal muscle loss during neoadjuvant chemotherapy predicts poor prognosis in patients with breast cancer
    Masatsugu Amitani
    Takaaki Oba
    Nami Kiyosawa
    Hiroki Morikawa
    Tatsunori Chino
    Ai Soma
    Tadafumi Shimizu
    Koichi Ohno
    Mayu Ono
    Tokiko Ito
    Toshiharu Kanai
    Kazuma Maeno
    Ken-ichi Ito
    [J]. BMC Cancer, 22
  • [8] Skeletal muscle loss during neoadjuvant chemotherapy predicts poor prognosis in patients with breast cancer
    Amitani, Masatsugu
    Oba, Takaaki
    Kiyosawa, Nami
    Morikawa, Hiroki
    Chino, Tatsunori
    Soma, Ai
    Shimizu, Tadafumi
    Ohno, Koichi
    Ono, Mayu
    Ito, Tokiko
    Kanai, Toshiharu
    Maeno, Kazuma
    Ito, Ken-ichi
    [J]. BMC CANCER, 2022, 22 (01)
  • [9] Tumor localization for breast cancer patients receiving neoadjuvant chemotherapy
    Zhen-Yu Wu
    Namkug Kim
    BeomSeok Ko
    [J]. Breast Cancer Research and Treatment, 2021, 185 : 531 - 532
  • [10] Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy
    Tari A. King
    Monica Morrow
    [J]. Nature Reviews Clinical Oncology, 2015, 12 : 335 - 343